Ocular toxicity of fludarabine: a purine analog

Authors: Ding, Xiaoyan; Herzlich, Alexandra A; Bishop, Rachel; Tuo, Jingsheng; Chan, Chi-Chao

Source: Expert Review of Ophthalmology, Volume 3, Number 1, February 2008 , pp. 97-109(13)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The purine analogs, fludarabine and cladribine represent an important class of chemotherapy agents used to treat a broad spectrum of lymphoid malignancies. Their toxicity profiles include dose-limiting myelosuppression, immunosuppression, opportunistic infection and severe neurotoxicity. This review summarizes the neurotoxicity of high- and standard-dose fludarabine, focusing on the clinical and pathological manifestations in the eye. The mechanisms of ocular toxicity are probably multifactorial. With increasing clinical use, an awareness of the neurological and ocular vulnerability, particularly to fludarabine, is important owing to the potential for life- and sight-threatening consequences.

Keywords: fludarabine; neurotoxicity; ocular toxicity; ophthalmic pathology; pharmacogenetics; purine analog

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469899.3.1.97

Affiliations: 1: Section of Immunopathology, Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA; And, Zhongshan Ophthalmic Center, Sun Yet-sen University, Guangzhou, China

Publication date: 2008-02-01

More about this publication?

Expert Review of Ophthalmology provides an important platform for commentary and debate on current and emerging approaches in ocular medicine.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites